Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 28, 2022 07:00 ET | Source: Tango Therapeutics, Inc.

Tango Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer...
February 02, 2022 07:00 ET | Source: Tango Therapeutics, Inc.

Tango Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer...
January 24, 2022 07:00 ET | Source: Tango Therapeutics, Inc.

Tango Therapeutics Announces Clearance of TNG908 IND by FDA and Recent Pipeline Progress Updates

- TNG908 IND cleared by FDA, Phase 1/2 trial expected to start in 1H 2022 - Additional pipeline programs progressing throughout 2022 CAMBRIDGE, Mass., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Tango...
November 11, 2021 07:00 ET | Source: Tango Therapeutics, Inc.

Tango Therapeutics to Participate in the Jefferies London Healthcare Conference

CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer...
November 09, 2021 07:00 ET | Source: Tango Therapeutics, Inc.

Tango Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlights

- Strong cash position of $504 million supports advancing discovery and clinical pipeline into second half of 2024 - - On track for IND filing in fourth quarter of 2021 for TNG908, an...
November 01, 2021 07:00 ET | Source: Tango Therapeutics, Inc.

Tango Therapeutics Announces Appointment of Dr. Marc Rudoltz as Chief Medical Officer and Doug Barry as General Counsel

CAMBRIDGE, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer...
August 10, 2021 09:00 ET | Source: Tango Therapeutics, Inc.

Tango Therapeutics Debuts as Publicly Traded Precision Oncology Company Focused on the Next Generation of Targeted Cancer Therapies

– Business combination transaction with BCTG Acquisition Corp., a special purpose acquisition company sponsored by Boxer Capital, completed today – – Combined company Tango Therapeutics, Inc. will...